---
schema_version: "secwatch.filing_event.v1"
accession: "0001200375-24-000013"
form_type: "8-K"
ticker: "CDXS"
cik: "0001200375"
company_name: "CODEXIS, INC."
filed_at: "2024-05-02T23:59:59+00:00"
generated_at: "2026-06-02T23:58:05.768181+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Codexis Q1 revenue up 32%, net loss narrows to $11.5M; reiterates FY guidance

## Summary
- Total revenue $17.1M (+32% YoY); product revenue $9.6M (+14%); net loss $11.5M vs $22.6M loss in Q1 2023.
- Received first large pharma order for dsRNA ligase (low-to-mid single digit million) and entered $40M loan facility with Innovatus.
- Reiterated FY 2024 guidance: product rev $38-42M, R&D rev $18-22M, product gross margin 58-63%.
- Cash and investments $85.5M; expects to fund operations through positive cash flow by end of 2026.
- Exclusive license with Roche for dsDNA ligase; sold HCU and MSUD compounds.

## SEC filing metadata
- accession: 0001200375-24-000013
- form_type: 8-K
- ticker: CDXS
- cik: 0001200375
- company_name: CODEXIS, INC.
- filed_at: 2024-05-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1200375/000120037524000013/0001200375-24-000013-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1200375/000120037524000013/cdxs-20240502.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001200375-24-000013
- JSON: https://secwatch.observer/filing/0001200375-24-000013.json
- Plain text: https://secwatch.observer/filing/0001200375-24-000013.txt

## Key facts
- Earnings Releases
  CODEXIS, INC. reported the first quarter ended March 31, 2024 results: revenue $17.1 million. Guidance reaffirmed.
  - Period: the first quarter ended March 31, 2024
  - Revenue: $17.1 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: in the second half of 2025, ahead of an anticipated full commercial launch of the platform in 2026. First Quarter 2024 Financial Highlights • Total revenues increased by 32% to $17.1 million for first quarter 2024 compared to $13.0 million in first quarter 2023. • Product revenues increased by 14% to $9.6 million for first quarter 2024 compared to $8.4 million in
  evidence_url: https://www.sec.gov/Archives/edgar/data/1200375/000120037524000013/0001200375-24-000013-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.